ANI PHARMACEUTICALS INC (ANIP) competitors & alternatives
Health Care · NASDAQ
ANI PHARMACEUTICALS INC (ANIP)'s top competitors and alternatives — its most similar public companies — include AMNEAL PHARMACEUTICALS INC CLASS A (AMRX), Organon & Co. (OGN), CLIMB BIO INC (CLYM), ALLOGENE THERAPEUTICS INC (ALLO), CARTESIAN THERAPEUTICS INC (RNAC), NKARTA INC (NKTX), IMMUNOVANT INC (IMVT), CATALYST PHARMACEUTICALS INC (CPRX), AMPHASTAR PHARMACEUTICALS INC (AMPH), GLAUKOS CORP (GKOS), Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS). These are ANI PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ANIP competitors & alternatives
-
AMNEAL PHARMACEUTICALS INC CLASS AAMRXHealth Care
Amneal Pharmaceuticals is a diversified biopharma company providing a broad range of essential, affordable generic and specialty medicines, alongside…
$17.75 (as of 2026-07-22) · market cap $5.7B
-
Organon & Co.OGNHealth Care
A diversified pharmaceutical company spun from Merck focusing on established branded medicines and medical devices for women's health, infectious disease, and…
$13.52 (as of 2026-07-22) · market cap $3.6B
-
CLIMB BIO INCCLYMHealth Care
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and…
$12.58 (as of 2026-07-22) · market cap $720M
-
ALLOGENE THERAPEUTICS INCALLOHealth Care
Allogene Therapeutics is pioneering off-the-shelf, donor-derived CAR T cell therapies to provide more scalable and accessible cancer and autoimmune disease…
$1.86 (as of 2026-07-22) · market cap $637M
-
CARTESIAN THERAPEUTICS INCRNACHealth Care
Cartesian Therapeutics is pioneering mRNA-engineered cell therapies designed to provide a precision immune reset for patients with autoimmune diseases,…
$8.13 (as of 2026-07-22) · market cap $238M
-
NKARTA INCNKTXHealth Care
Nkarta is a clinical-stage biotech developing off-the-shelf, engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases through…
$2.41 (as of 2026-07-22) · market cap $172M
-
IMMUNOVANT INCIMVTHealth Care
Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by…
$39.05 (as of 2026-07-22) · market cap $8.0B
-
CATALYST PHARMACEUTICALS INCCPRXHealth Care
Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from…
$31.49 (as of 2026-07-21) · market cap $3.9B
-
AMPHASTAR PHARMACEUTICALS INCAMPHHealth Care
Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging…
$19.30 (as of 2026-07-22) · market cap $864M
-
GLAUKOS CORPGKOSHealth Care
Glaukos is a specialized ophthalmic company transforming eye care through innovative Micro-Invasive Glaucoma Surgery devices and proprietary sustained-release…
$152.86 (as of 2026-07-22) · market cap $8.9B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
ViatrisVTRSHealth Care
A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more…
$17.01 (as of 2026-07-22) · market cap $20.0B
Not quite? Describe exactly what you want →
Peers are ANI PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ANI PHARMACEUTICALS INC (ANIP).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.